Skip to main content
Search

Cardiac stem cell therapy

Published on July 31, 2024   51 min

A selection of talks on Cardiovascular & Metabolic

Please wait while the transcript is being prepared...
0:00
My name is Joshua M. Hare, M.D. I am a professor of medicine at the Miller School of Medicine at the University of Miami. Today, I'm going to speak to you about cardiac stem cell therapy.
0:16
There has been a long-standing quest to repair the damaged heart with cell-based therapy that goes back to the 1990s, at which time there were early attempts using skeletal myoblasts to repair damaged hearts in preclinical models. In the early 2000s, investigators turned their interest to answering the question of whether tissues like the bone marrow contain a compartment of cells with tissue reparative properties. Since that time there's been an extensive amount of work using adult type cell-based therapy from bone marrow and other types of tissues. But this has been accompanied by very substantial controversy over whether such cells have true differentiation capacity. In other words, can these cells engraft and differentiate into a host tissue like the heart? This field however has continued to produce provocative data and there are ongoing clinical trials to this date. The current state of the art in the 2020s is to explore programs that have developed on the earlier work that use, for example, combination cell therapy, combining different types of cells to optimize a result, combining cell with gene therapy and finally, we are starting to see the clinical development of pluripotent stem cells, again alone or in combination. I will cover each of these topics in the lecture. Another approach that I won't cover in this lecture is whether or not we can improve tissue repair by using tissue engineering approaches as compared to just cell-based therapy alone. But the topic for today is cell-based therapy alone.

Quiz available with full talk access. Request Free Trial or Login.